Clinical Trial Update: CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial CELTIC-1 evaluating cerdulatinib in relapsed/refractory peripheral T-cell lymphoma has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma Type
• Enteropathy-associated T-cell Lymphoma Type Ii
• Follicular T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Megakaryoblastic Leukemia-like T-cell Lymphoma
• Nasal Lymphoma
• Nodal Lymphomas of Follicular Helper
• Peripheral T-cell Lymphoma

Drugs mentioned

• cerdulatinib (cerdulatinib)

Snippet

Sponsor: Portola Pharmaceuticals | Conditions: Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH) | Phase 2, Phase 3 | Status: WITHDRAWN